Sangamo Therapeutics, Inc.
0.12USD
+0.0000 (+0.00%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on SGMOQ.
| In $M except per-share | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 14 | 1 | 18 | 6 | 8 | 49 | 0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -32 | -38 | -36 | -18 | -30 | -26 | 11 | -37 |
| Net Income | -31 | -37 | -35 | -20 | -31 | -23 | 11 | -36 |
| EPS (Diluted) | -$0.08 | -$0.11 | -$0.11 | -$0.08 | -$0.14 | -$0.12 | $0.04 | -$0.18 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)